Summit Therapeutics (NASDAQ: SMMT) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum‑containing chemotherapy for patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) who have received prior EGFR tyrosine kinase inhibitor (TKI) therapy. The CRL states that the BLA cannot be approved in its present form, as the FDA determined that substantial evidence of effectiveness has not been established in the absence of a statistically significant overall survival (OS) improvement.
Regulatory Decision
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Action | Complete Response Letter (CRL) – BLA cannot be approved in its present form |
| Product | Ivonescimab + platinum‑containing chemotherapy |
| Indication Sought | Locally advanced or metastatic NSCLC after prior EGFR TKI therapy |
| FDA Rationale | Substantial evidence of effectiveness not established without a statistically significant OS improvement; PFS benefit alone deemed insufficient to support a positive benefit‑risk profile for approval |
| Announcement Date | 15 November 2026 |
Drug Profile & Mechanism of Action
- Molecule: Ivonescimab – a novel, potential first‑in‑class investigational bispecific antibody combining PD‑1 blockade immunotherapy with VEGF blockade anti‑angiogenesis in a single molecule.
- Design Differentiator: Demonstrates unique cooperative binding to each intended target, exhibiting multifold higher affinity to PD‑1 in the presence of VEGF – a tumor‑microenvironment–conditional binding mechanism intended to concentrate activity at disease sites.
- Origin: Independently developed by Akeso (HKG: 9926) and out‑licensed to Summit Therapeutics.
Partnership & Transaction History
- December 2022: Akeso out‑licensed ivonescimab to Summit under an agreement granting exclusive rights to develop and commercialize the drug in the United States, Canada, Europe, and Japan, in a deal valued at up to USD 5 billion.
- June 2024: The licensing territory was expanded to grant Summit exclusive development and commercialization rights across Central America, South America, the Middle East, and Africa.
- September 2026: Summit entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), under which AstraZeneca made a USD 2 billion equity investment in Summit via convertible preferred stock and initiated a clinical collaboration evaluating ivonescimab in combination with sonesitatug vedotin (sone‑ve).
Market Impact & Outlook
- Regulatory Precedent: The FDA’s position that a PFS benefit without statistically significant OS improvement does not support approval signals a stringent effectiveness standard for combination immunotherapy regimens in the post‑EGFR TKI NSCLC setting – with implications beyond ivonescimab for bispecific programs pursuing accelerated or PFS‑anchored pathways.
- Path Forward Considerations: Addressing the CRL would likely require additional evidence of an OS benefit; the specific pathway and timing were not disclosed in the announcement.
- Franchise Underpinning: Ivonescimab remains central to Summit’s valuation, the Akeso partnership economics of up to USD 5 billion, and AstraZeneca’s USD 2 billion equity stake and combination collaboration with sone‑ve – all now tied to resolving the FDA’s effectiveness concerns.
- Global Footprint Intact: The CRL affects the U.S. BLA only; Summit retains exclusive rights across the Americas, Europe, Japan, the Middle East, and Africa, and development in other territories is unaffected by the FDA action.
- Competitive Context: The post‑EGFR TKI NSCLC market remains an area of high unmet need, with chemotherapy‑based standards of care – a commercially significant opportunity should the OS evidence question ultimately be resolved.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding ivonescimab’s regulatory status, potential pathways to address the Complete Response Letter, clinical development plans, the AstraZeneca collaboration, and commercial expectations. Actual results may differ due to risks including further regulatory requirements, clinical trial outcomes, OS data maturation, partnership dynamics, and competitive developments.-Fineline Info & Tech
